Formosa Laboratories Inc.

Formosa Laboratories was established in 1995, and entered GMP API manufacturing in 2000. With strong R&D capabilities and a robust quality management system, the company has established a solid presence in the global biopharmaceutical industry. Taiyao Chemical markets a broad portfolio of APIs worldwide and provides CDMO (Contract Development and Manufacturing Organization) services, including development and manufacturing of Antibody-Drug Conjugates (ADCs). Since 2018, Taiyao Chemical has expanded into sterile injectables, offering vertically integrated, one-stop services for both cytotoxic and non-cytotoxic injectable products, including aseptic filling and lyophilized formulations. The company is ISO certified and operates in full compliance with cGMP standards. Its manufacturing facilities have successfully passed GMP inspections by the Taiwan Food and Drug Administration (TFDA), the U.S. Food and Drug Administration (FDA), Germany’s BGV, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Taiyao Chemical’s products and services are supplied to markets across Europe, the United States, Japan, and other regions worldwide.